IBA extends BV Cyclotron partnership to include PET tracers

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

Ion Beam Applications (IBA) and Amsterdam-based BV Cyclotron (BVC) have signed a new agreement for the production and distribution of 18F-labeled radiopharmaceuticals used in PET.

The partnership follows two agreements, signed in 2007 and 2008, between IBA and BVC to produce and distribute Iodine-124 and Zirconium-89. The new agreement calls for IBA to become the exclusive distributor of 18F-FDG and other 18F-labelled compounds produced by BVC, starting Jan. 1, 2010.

By adding the production site of Amsterdam, IBA said its PET radiopharmaceuticals production and distribution network will be supported by 53 facilities worldwide.

The Louvain-la-Neuve, Belgium-based IBA said it is currently in the process of obtaining market authorization for 18F-DOPA and 18F-NaF, and will start the registration process for several other new PET compounds in the coming years. BVC will produce those radiopharmaceuticals and IBA will distribute them to the Dutch and Belgian nuclear medicine communities.